12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Company News  |  Deals

NanoBio, Merck deal

The partners will evaluate combining Merck's respiratory syncytial virus (RSV) antigen and NanoBio's NanoStat adjuvant technology for...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >